- Home
- IMMP vs NGNE Comparison
IMMP vs NGNE Comparison
Compare IMMP & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMP
- NGNE
- Stock Information
- Founded
- IMMP 1987
- NGNE 2003
- Country
- IMMP Australia
- NGNE United States
- Employees
- IMMP N/A
- NGNE N/A
- Industry
- IMMP Biotechnology: Pharmaceutical Preparations
- NGNE Biotechnology: Pharmaceutical Preparations
- Sector
- IMMP Health Care
- NGNE Health Care
- Exchange
- IMMP Nasdaq
- NGNE Nasdaq
- Market Cap
- IMMP 221.2M
- NGNE 251.9M
- IPO Year
- IMMP N/A
- NGNE N/A
- Fundamental
- Price
- IMMP $1.72
- NGNE $20.09
- Analyst Decision
- IMMP Buy
- NGNE Strong Buy
- Analyst Count
- IMMP 1
- NGNE 7
- Target Price
- IMMP $7.00
- NGNE $41.86
- AVG Volume (30 Days)
- IMMP 98.8K
- NGNE 240.1K
- Earning Date
- IMMP 02-27-2025
- NGNE 08-08-2025
- Dividend Yield
- IMMP N/A
- NGNE N/A
- EPS Growth
- IMMP N/A
- NGNE N/A
- EPS
- IMMP N/A
- NGNE N/A
- Revenue
- IMMP $3,019,249.00
- NGNE $925,000.00
- Revenue This Year
- IMMP $50.37
- NGNE N/A
- Revenue Next Year
- IMMP N/A
- NGNE N/A
- P/E Ratio
- IMMP N/A
- NGNE N/A
- Revenue Growth
- IMMP 24.11
- NGNE N/A
- 52 Week Low
- IMMP $1.32
- NGNE $6.88
- 52 Week High
- IMMP $2.72
- NGNE $74.49
- Technical
- Relative Strength Index (RSI)
- IMMP 50.07
- NGNE 57.57
- Support Level
- IMMP $1.53
- NGNE $14.65
- Resistance Level
- IMMP $1.71
- NGNE $18.21
- Average True Range (ATR)
- IMMP 0.07
- NGNE 1.84
- MACD
- IMMP 0.01
- NGNE 0.03
- Stochastic Oscillator
- IMMP 72.41
- NGNE 80.24
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.